Xigris licence withdrawn

Xigris was indicated for the treatment of severe sepsis with multiple organ failure | SCIENCE PHOTO LIBRARY
Xigris was indicated for the treatment of severe sepsis with multiple organ failure | SCIENCE PHOTO LIBRARY

Xigris (activated drotrecogin alfa) has been withdrawn by Lilly after it failed to show a survival benefit in a clinical trial in patients with septic shock.

Results from the PROWESS-SHOCK study showed the overall 28-day mortality was 26.4% in drotrecogin-alfa-treated patients (n=846) compared with 24.2% in patients given placebo (n=834; p=0.31). No new safety findings were observed.

Drotrecogin alfa must not be initiated in new patients and should be discontinued in patients currently receiving treatment.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...